# CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

> **NCT06081478** · PHASE2 · RECRUITING · sponsor: **Beijing Tongren Hospital** · enrollment: 100 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- B-cell Lymphoma
- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** CD19/CD22-bispecific CAR-T cells

## Key facts

- **NCT ID:** NCT06081478
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-18
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06081478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06081478, "CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06081478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*